- Home
- ZNTL vs LFT Comparison
ZNTL vs LFT Comparison
Compare ZNTL & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- LFT
- Stock Information
- Founded
- ZNTL 2014
- LFT 2012
- Country
- ZNTL United States
- LFT United States
- Employees
- ZNTL N/A
- LFT N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- LFT Real Estate Investment Trusts
- Sector
- ZNTL Health Care
- LFT Real Estate
- Exchange
- ZNTL Nasdaq
- LFT Nasdaq
- Market Cap
- ZNTL 137.9M
- LFT 134.4M
- IPO Year
- ZNTL 2020
- LFT N/A
- Fundamental
- Price
- ZNTL $1.29
- LFT $2.63
- Analyst Decision
- ZNTL Buy
- LFT Buy
- Analyst Count
- ZNTL 8
- LFT 3
- Target Price
- ZNTL $8.53
- LFT $2.50
- AVG Volume (30 Days)
- ZNTL 927.8K
- LFT 147.4K
- Earning Date
- ZNTL 05-06-2025
- LFT 05-08-2025
- Dividend Yield
- ZNTL N/A
- LFT 15.68%
- EPS Growth
- ZNTL N/A
- LFT 18.59
- EPS
- ZNTL N/A
- LFT 0.34
- Revenue
- ZNTL $67,425,000.00
- LFT $36,218,717.00
- Revenue This Year
- ZNTL N/A
- LFT $172.71
- Revenue Next Year
- ZNTL N/A
- LFT $0.46
- P/E Ratio
- ZNTL N/A
- LFT $7.74
- Revenue Growth
- ZNTL N/A
- LFT 12.91
- 52 Week Low
- ZNTL $1.01
- LFT $2.22
- 52 Week High
- ZNTL $13.46
- LFT $2.84
- Technical
- Relative Strength Index (RSI)
- ZNTL 39.50
- LFT 52.67
- Support Level
- ZNTL $1.01
- LFT $2.22
- Resistance Level
- ZNTL $1.32
- LFT $2.64
- Average True Range (ATR)
- ZNTL 0.14
- LFT 0.13
- MACD
- ZNTL 0.02
- LFT 0.01
- Stochastic Oscillator
- ZNTL 37.33
- LFT 93.18
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.